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DNMT = DNA methyl transferase, EGFR = epidermal growth factor receptor, ER = oestrogen receptor; ERK = extracellular signal regulated kinase,
MAPK = mitogen activated protein kinase, STI = signal transduction inhibitor.
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Introduction
Most breast cancers overexpress the oestrogen receptor
(ER)-α, and the ERα+ phenotype is relatively stable during
endocrine treatment and on subsequent treatment failure.
However, approximately 30% of tumours are ERα– at
diagnosis, while a proportion of tumours, which are initially
ERα+, lack the receptor at the time of tamoxifen relapse in
the adjuvant or metastatic setting. The mechanisms
underlying de novo and acquired ERα negativity remain
poorly-defined, although their elucidation is of obvious
therapeutic interest since the ERα– phenotype is
associated with endocrine resistance, aggressive tumour
biology and poor prognosis. Somatic mutations in the ERα
gene are quite rare and are therefore unlikely to explain the
frequency of ERα negativity. Epigenetic mechanisms,
notably CpG island methylation and histone deacetylation,
may contribute by silencing ERα gene transcription in
approximately 25% of de novo ERα– cancers [1].
Interestingly, ERα expression and function can be partially
recovered in ERα– models using the DNA methyl
transferase (DNMT) inhibitor aza-2-deoxycytidine, DNMT1
antisense, or the histone deacetylase inhibitor trichostatin
[2]. However, there is also emerging evidence that
sustained, exaggerated growth factor pathways [notably
those hyperactivating extracellular signal-regulated kinases
(ERK)1/2 mitogen activated protein kinase (MAPK)] may
promote substantial decline, and even total loss, of ERα. A
new article by Holloway and colleagues [3] sheds light on
this mechanism of ERα negativity, revealing that
exaggerated ERK1/2 MAPK signalling promotes ERα
downregulation via its impact on cytoplasmic substrates
that include the transcription factor nuclear factor kappa B
(NFκB).
Hyperactivation of ERK1/2 MAPK promotes
oestrogen receptor loss via cytoplasmic
substrates including NFκ κB
Growth factor pathways can enhance ERα
phosphorylation, transcriptional activity and cell growth in
the absence of ERα ligand. Paradoxically, a decline in
ERα expression may also be a possible outcome when
growth factor signalling is extreme, reminiscent of the ERα
downregulation that occurs during chronic receptor
activation by oestrogen [4]. Supportive evidence are
drawn from stable transfection studies where growth
factor signalling elements, notably those comprising the
epidermal growth factor receptor (EGFR)/HER2 pathway,
promote ERα loss when overexpressed in ERα+ breast
cancer cells. Oh and colleagues noted precipitous
decreases in ERα mRNA and protein in MCF-7 cells
transfected with constitutively active HER2, mitogen
activated kinase kinase 1 (MEK1), Raf-1 kinase (Raf1) or
ligand-activatable EGFR, all of which hyperactivate
ERK1/2 MAPK [5]. They also noted a loss of oestrogen-
mediated gene expression and oestrogen response
element (ERE) activity, and acquisition of endocrine
resistance. Interestingly, the phenomenon was reversible,
since abrogation of hyperactivated ERK1/2 MAPK
restored ERα  expression and activity. Extending these
studies, Holloway and colleagues have now begun to
decipher the mechanism of MAPK-mediated ERα loss in
these various transfected models. Using dominant
negative constructs, they show that hyperactivated
ERK1/2 MAPK downregulate ERα via a common
substrate. Use of an ERK2 deletion construct to prevent
nuclear MAPK activity reveals this substrate is
cytoplasmic. By examining potential MAPK substrates
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(again using appropriate dominant negatives), they
demonstrate that activator protein-1 (AP-1) and 90 kDa
ribsosomal S6 kinase 1 (RSK1) are not responsible for the
ER downregulation promoted by MAPK hyperactivation.
However, there does appear to be some importance for
NFκB. This growth-promoting transcription factor can be
cytoplasmically-activated (prior to its nuclear
translocation) via MAPK-mediated induction of autocrine
growth factors (e.g. heparin-binding EGF). Holloway and
colleagues demonstrate gross elevation of NFκB activity
in the various models exhibiting MAPK hyperactivation.
This NFκB activity is inhibited by abrogating ERK1/2
MAPK signalling. Importantly, blockade of NFκB activity
(e.g. using Parthenolide) restores ERα expression and
activity in parallel, although interestingly there was only
partial recovery indicating existence of additional
cytoplasmic substrates.
Conclusions
These new data obtained by Holloway and colleagues in
stable transfected cells are important in that they provide
proof of principle that extreme growth factor signalling,
resulting in ERK1/2 MAPK hyperactivation and
recruitment of cytoplasmic substrates including NFκB, is
capable of promoting ERα loss. Further molecular detail of
the receptor downregulation mechanism, determination of
growth factor signalling thresholds required to instigate
ERα loss, and the impact of hyperactivation of additional
signalling cascades (e.g. phosphatidylinositol 3′ kinase
[6]) is now required. Questions clearly remain regarding
relevance to ERα negativity de novo or acquired during
therapy. Significant, however, is the inverse ERα/EGFR
association in clinical disease and elevated ERK1/2
MAPK and NFκB signalling observed in ERα– cells [7,8].
Moreover, ERα transrepresses proinvasive genes and so
growth factor-mediated ERα loss may underlie poor
prognosis in ERα negative disease [6]. Finally, modestly
increased growth factor signalling activates ERα  in
acquired tamoxifen resistance, explaining subsequent
antihormone response; however, more extreme/prolonged
signalling might promote ERα negative endocrine
insensitivity in some patients during sequential endocrine
challenge [7].
While future studies are clearly required, the data from
Holloway and colleagues do have exciting ramifications for
possible therapeutic approaches in ERα– disease.
Manipulation of growth factor pathways (in particular
ERK1/2 MAPK and potentially NFκB signalling) with
signal transduction inhibitors (STIs) might feasibly recover
ERα positivity in ERα– cells, hence restoring sensitivity to
antioestrogen if used in combination. Importantly, the
group demonstrate that in vitro pharmacological or
dominant negative blockade of ERK1/2 MAPK signalling
does re-instate physiological levels of ERα expression and
function in their stable-transfected cells. Of course, we
must await future experimental consolidation and
appropriate clinical examination, but a compelling
preliminary study demonstrates that reversion of ERα
negativity and re-instatement of endocrine responsiveness
occurs in a proportion of advanced HER2+ breast cancer
patients using Herceptin to inhibit growth factor signalling
[9]. Since this mechanism may only be applicable in
tumours without epigenetic ERα  silencing, combination
therapy of STIs plus appropriate strategies to abrogate ER
methylation/deacetylation could prove worthy of future
exploration. However, DNMT1 can be growth factor-
regulated and so perhaps sustained increases in growth
factor signalling ultimately culminate in ERα promoter
silencing. If so, STIs might also prove effective in restoring
ERα where there is ERα promoter hypermethylation.
Intriguingly, pharmacological inhibition of Ras signalling
does reverse gene methylation events in other cancer
models via downregulating DNMT1 [10].
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